相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant
Chieh-Hsin Lin et al.
CURRENT DRUG TARGETS (2020)
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Chun-Hung Chang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial
Erica D. Diminich et al.
SCHIZOPHRENIA RESEARCH (2020)
Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute D-cycloserine
Jennifer K. Forsyth et al.
SCHIZOPHRENIA BULLETIN (2017)
Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study
Kazuo Takiguchi et al.
BMC PSYCHIATRY (2017)
Schizophrenia: from dopaminergic to glutamatergic interventions
Marc Laruelle
CURRENT OPINION IN PHARMACOLOGY (2014)
D-Cycloserine augmentation of cognitive remediation in schizophrenia
Christopher K. Cain et al.
SCHIZOPHRENIA RESEARCH (2014)
Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
Benjamin Rolland et al.
BIOMED RESEARCH INTERNATIONAL (2014)
NMDA Receptor Activity in Neuropsychiatric Disorders
Shaheen E. Lakhan et al.
Frontiers in Psychiatry (2013)
NMDA receptors, cognition and schizophrenia - Testing the validity of the NMDA receptor hypofunction hypothesis
Gary Gilmour et al.
NEUROPHARMACOLOGY (2012)
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Jennifer D. Gottlieb et al.
SCHIZOPHRENIA RESEARCH (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression
Maxwell Bennett
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
Donald C. Goff et al.
SCHIZOPHRENIA RESEARCH (2008)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Glutamatergic drugs for schizophrenia
H. J. Tuominen et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
DC Goff et al.
PSYCHOPHARMACOLOGY (2005)
Selective cognitive impairments associated with NMDA receptor blockade in humans
LM Rowland et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine
DA Yurgelun-Todd et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2005)
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
HJ Tuominen et al.
SCHIZOPHRENIA RESEARCH (2005)
Effects of D-cycloserine on negative symptoms in schizophrenia
EJ Duncan et al.
SCHIZOPHRENIA RESEARCH (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
U Heresco-Levy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
D-Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function
R Dall'Olio et al.
BEHAVIOURAL PHARMACOLOGY (2000)
分享论文
